{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T06:03:04Z","timestamp":1777442584186,"version":"3.51.4"},"reference-count":127,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,6,13]],"date-time":"2023-06-13T00:00:00Z","timestamp":1686614400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:p><jats:bold>Introduction:<\/jats:bold> In the last few decades, there has been a rapid development in cancer therapies and improved detection strategies, hence the death rates caused by cancer have decreased. However, it has been reported that cardiovascular disease has become the second leading cause of long-term morbidity and fatality among cancer survivors. Cardiotoxicity from anticancer drugs affects the heart\u2019s function and structure and can occur during any stage of the cancer treatments, which leads to the development of cardiovascular disease.<\/jats:p><jats:p><jats:bold>Objectives:<\/jats:bold> To investigate the association between anticancer drugs for non-small cell lung cancer (NSCLC) and cardiotoxicity as to whether: different classes of anticancer drugs demonstrate different cardiotoxicity potentials; different dosages of the same drug in initial treatment affect the degree of cardiotoxicity; and accumulated dosage and\/or duration of treatments affect the degree of cardiotoxicity.<\/jats:p><jats:p><jats:bold>Methods:<\/jats:bold> This systematic review included studies involving patients over 18\u00a0years old with NSCLC and excluded studies in which patients\u2019 treatments involve radiotherapy only. Electronic databases and registers including Cochrane Library, National Cancer Institute (NCI) Database, PubMed, Scopus, Web of Science, ClinicalTrials.gov and the European Union Clinical Trials Register were systematically searched from the earliest available date up until November 2020. A full version protocol of this systematic review (CRD42020191760) had been published on PROSPERO.<\/jats:p><jats:p><jats:bold>Results:<\/jats:bold> A total of 1785 records were identified using specific search terms through the databases and registers; 74 eligible studies were included for data extraction. Based on data extracted from the included studies, anticancer drugs for NSCLC that are associated with cardiovascular events include bevacizumab, carboplatin, cisplatin, crizotinib, docetaxel, erlotinib, gemcitabine and paclitaxel. Hypertension was the most reported cardiotoxicity as 30 studies documented this cardiovascular adverse event. Other reported treatment-related cardiotoxicities include arrhythmias, atrial fibrillation, bradycardia, cardiac arrest, cardiac failure, coronary artery disease, heart failure, ischemia, left ventricular dysfunction, myocardial infarction, palpitations, and tachycardia.<\/jats:p><jats:p><jats:bold>Conclusion:<\/jats:bold> The findings of this systematic review have provided a better understanding of the possible association between cardiotoxicities and anticancer drugs for NSCLC. Whilst variation is observed across different drug classes, the lack of information available on cardiac monitoring can result in underestimation of this association.<\/jats:p><jats:p><jats:bold>Systematic Review Registration:<\/jats:bold><jats:ext-link>https:\/\/www.crd.york.ac.uk\/prospero\/display_record.php?ID=CRD42020191760<\/jats:ext-link>, identifier PROSPERO CRD42020191760.<\/jats:p>","DOI":"10.3389\/fphar.2023.1137983","type":"journal-article","created":{"date-parts":[[2023,6,13]],"date-time":"2023-06-13T04:41:22Z","timestamp":1686631282000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":13,"title":["Identification of cardiotoxicity related to non-small cell lung cancer (NSCLC) treatments: A systematic review"],"prefix":"10.3389","volume":"14","author":[{"given":"Stefanie Ho Yi","family":"Chan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasmin","family":"Khatib","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sherael","family":"Webley","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Deborah","family":"Layton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sam","family":"Salek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2023,6,13]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1930","DOI":"10.1111\/cas.13623","article-title":"Osimertinib in Japanese patients with EGFR T790M mutation-positive advanced non-small-cell lung cancer: AURA3 trial","volume":"109","author":"Akamatsu","year":"2018","journal-title":"Cancer Sci."},{"key":"B2","doi-asserted-by":"publisher","first-page":"3690","DOI":"10.1111\/bcp.14793","article-title":"Cardiovascular safety of the tyrosine kinase inhibitor nintedanib","volume":"87","author":"Ameri","year":"2021","journal-title":"Br. J. Clin. Pharmacol."},{"key":"B3","article-title":"A phase III, double-blind, randomised, placebo-controlled study to assess the efficacy and safety of selumetinib (AZD6244; ARRY-142886) (Hyd-Sulfate) in combination with docetaxel","volume-title":"Patients receiving second line treatment for KRAS mutation-positive locally advanced or metastatic non small cell lung cancer (stage IIIB - IV) (SELECT 1) (clinical trial registration No. NCT01933932)","year":"2021"},{"key":"B4","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1016\/j.jtho.2017.01.022","article-title":"Maintenance sunitinib following initial platinum-based combination chemotherapy in advanced-stage IIIB\/IV non\u2013small cell lung cancer: A randomized, double-blind, placebo-controlled phase III study\u2014CALGB 30607 (alliance)","volume":"12","author":"Baggstrom","year":"","journal-title":"J. Thorac. Oncol."},{"key":"B5","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1016\/j.jtho.2017.01.022","article-title":"Maintenance sunitinib following initial platinum-based combination chemotherapy in advanced-stage IIIB\/IV non-small cell lung cancer: A randomized, double-blind, placebo-controlled phase III study-CALGB 30607 (alliance)","volume":"12","author":"Baggstrom","year":"","journal-title":"J. Thorac. Oncol. Off. Publ. Int. Assoc. Study Lung Cancer"},{"key":"B6","doi-asserted-by":"publisher","first-page":"1468","DOI":"10.1016\/S1470-2045(18)30673-9","article-title":"Avelumab versus docetaxel in patients with platinum-treated advanced non-small-cell lung cancer (JAVELIN lung 200): An open-label, randomised, phase 3 study","volume":"19","author":"Barlesi","year":"2018","journal-title":"Lancet Oncol."},{"key":"B7","first-page":"5477","article-title":"An ELCWP phase III trial comparing ifosfamide and cisplatin regimens in advanced NSCLC","volume":"33","author":"Berghmans","year":"2013","journal-title":"Anticancer Res."},{"key":"B8","doi-asserted-by":"publisher","first-page":"e1918070","DOI":"10.1001\/jamanetworkopen.2019.18070","article-title":"Effect of concurrent chemoradiation with celecoxib vs concurrent chemoradiation alone on survival among patients with non\u2013small cell lung cancer with and without cyclooxygenase 2 genetic variants: A phase 2 randomized clinical trial","volume":"2","author":"Bi","year":"2019","journal-title":"JAMA Netw. Open"},{"key":"B9","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1158\/1078-0432.CCR-09-1675","article-title":"Phase 1b study of motesanib, an oral angiogenesis inhibitor, in combination with carboplatin\/paclitaxel and\/or panitumumab for the treatment of advanced non-small cell lung cancer","volume":"16","author":"Blumenschein","year":"2010","journal-title":"Clin. Cancer Res."},{"key":"B10","doi-asserted-by":"publisher","first-page":"48","DOI":"10.7812\/TPP\/14-241","article-title":"Breast cancer survivorship: A comprehensive review of long-term medical issues and lifestyle recommendations","volume":"19","author":"Bodai","year":"2019","journal-title":"Perm. J."},{"key":"B11","volume-title":"A randomised, open-label, Phase III study of BIBW 2992 versus chemotherapy as first-line treatment for patients with stage IIIB or IV adenocarcinoma of the lung harbouring an EGFR activating mutation (clinical trial registration No. NCT00949650)","year":""},{"key":"B12","volume-title":"LUX-lung 6: A randomized, open-label, Phase III study of BIBW 2992 versus chemotherapy as first-line treatment for patients with stage IIIB or IV adenocarcinoma of the lung harbouring an egfr activating mutation (clinical trial registration No. NCT01121393)","year":""},{"key":"B13","volume-title":"LUX-lung 7: A randomised, open-label Phase IIb trial of afatinib versus gefitinib as first-line treatment of patients with egfr mutation positive advanced adenocarcinoma of the lung (clinical trial registration No. NCT01466660)","year":"2020"},{"key":"B14","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1200\/JCO.2000.18.3.623","article-title":"Comparison of survival and quality of life in advanced non-small-cell lung cancer patients treated with two dose levels of paclitaxel combined with cisplatin versus etoposide with cisplatin: Results of an eastern cooperative oncology group trial","volume":"18","author":"Bonomi","year":"2000","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"1","DOI":"10.4172\/2329-9517.1000345","article-title":"Cardiotoxicity of first-line chemotherapy in patients with advanced non-small cell lung cancer","volume":"9","author":"Burs\u00e1c","year":"2018","journal-title":"J. Biodivers. Endanger. Species"},{"key":"B16","doi-asserted-by":"publisher","first-page":"5777","DOI":"10.1200\/JCO.2007.13.0856","article-title":"Randomized phase II study of gemcitabine plus cisplatin or carboplatin [corrected], with or without cetuximab, as first-line therapy for patients with advanced or metastatic non small-cell lung cancer","volume":"25","author":"Butts","year":"2007","journal-title":"J. Clin. Oncol."},{"key":"B17","doi-asserted-by":"publisher","first-page":"2027","DOI":"10.1056\/NEJMoa1810171","article-title":"Brigatinib versus crizotinib in ALK-positive non-small-cell lung cancer","volume":"379","author":"Camidge","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"B18","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1016\/j.lungcan.2006.03.004","article-title":"A randomized phase II trial evaluating standard (50 mg\/min) versus low (10 mg\/min) infusion duration of gemcitabine as first-line treatment in advanced non-small-cell lung cancer patients who are not eligible for platinum-based chemotherapy","volume":"52","author":"Cappuzzo","year":"2006","journal-title":"Lung Cancer Amst. Neth."},{"key":"B19","doi-asserted-by":"publisher","first-page":"8863789","DOI":"10.1155\/2021\/8863789","article-title":"Role of oxidative stress in the mechanisms of anthracycline-induced cardiotoxicity: Effects of preventive strategies","volume":"2021","author":"Carrasco","year":"2021","journal-title":"Oxid. Med. Cell. Longev."},{"key":"B20","volume-title":"Identification of cardiotoxicity related to cancer treatments: A systematic review","author":"Chan","year":"2020"},{"key":"B21","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1093\/jnci\/85.5.388","article-title":"Phase II study of taxol, merbarone, and piroxantrone in stage IV non-small-cell lung cancer: The Eastern Cooperative Oncology Group Results","volume":"85","author":"Chang","year":"1993","journal-title":"J. Natl. Cancer Inst."},{"key":"B22","doi-asserted-by":"publisher","first-page":"1308","DOI":"10.1097\/JTO.0b013e3182a02546","article-title":"Phase 2 study of pemetrexed plus carboplatin, or pemetrexed plus cisplatin with concurrent radiation therapy followed by pemetrexed consolidation in patients with favorable-prognosis inoperable stage IIIA\/B non-small-cell lung cancer","volume":"8","author":"Choy","year":"2013","journal-title":"J. Thorac. Oncol."},{"key":"B23","doi-asserted-by":"publisher","first-page":"3346","DOI":"10.3390\/jcm9103346","article-title":"Hypertensive cardiotoxicity in cancer treatment\u2014systematic analysis of adjunct, conventional chemotherapy, and novel therapies\u2014epidemiology, incidence, and pathophysiology","volume":"9","author":"Chung","year":"2020","journal-title":"J. Clin. Med."},{"key":"B24","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.ejca.2020.02.022","article-title":"Weekly paclitaxel plus bevacizumab versus docetaxel as second- or third-line treatment in advanced non-squamous non-small-cell lung cancer: Results of the IFCT-1103 ULTIMATE study","volume":"131","author":"Cortot","year":"2020","journal-title":"Eur. J. Cancer"},{"key":"B25","doi-asserted-by":"publisher","first-page":"135","DOI":"10.15386\/cjmed-339","article-title":"Chemotherapy-induced cardiotoxicity: Pathophysiology and prevention","volume":"87","author":"Csapo","year":"2014","journal-title":"Med. Pharm. Rep."},{"key":"B26","doi-asserted-by":"publisher","first-page":"309","DOI":"10.3322\/caac.21341","article-title":"Cardiotoxicity of anticancer treatments: Epidemiology, detection, and management","volume":"66","author":"Curigliano","year":"2016","journal-title":"Ca. Cancer J. Clin."},{"key":"B27","doi-asserted-by":"publisher","first-page":"1949","DOI":"10.1093\/annonc\/mdx192","article-title":"Romana 3: A phase 3 safety extension study of anamorelin in advanced non-small-cell lung cancer (NSCLC) patients with cachexia","volume":"28","author":"Currow","year":"2017","journal-title":"Ann. Oncol."},{"key":"B28","doi-asserted-by":"publisher","first-page":"252","DOI":"10.3322\/caac.21235","article-title":"Cancer treatment and survivorship statistics, 2014: Cancer treatment and survivorship statistics, 2014. CA","volume":"64","author":"DeSantis","year":"2014","journal-title":"Cancer J. Clin."},{"key":"B29","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1042\/CS20200305","article-title":"Cardiotoxic effects of angiogenesis inhibitors","volume":"135","author":"Dobbin","year":"2021","journal-title":"Clin. Sci."},{"key":"B30","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1016\/j.lungcan.2004.05.009","article-title":"Randomized phase II feasibility study of combining the matrix metalloproteinase inhibitor BMS-275291 with paclitaxel plus carboplatin in advanced non-small cell lung cancer","volume":"46","author":"Douillard","year":"2004","journal-title":"Lung Cancer"},{"key":"B31","volume-title":"A randomised Phase 2 trial of pemetrexed and gefitinib versus gefitinib as first line treatment for patients with stage IV non-squamous non-small cell lung cancer with activating epidermal growth factor receptor mutations (clinical trial registration No. NCT01469000)","year":""},{"key":"B32","volume-title":"A randomized multicenter Phase III study of taxane\/carboplatin\/cetuximab versus taxane\/carboplatin as first-line treatment for patients with advanced\/metastatic non-small cell lung cancer (clinical trial registration No. NCT00112294)","year":"2015"},{"key":"B33","volume-title":"A randomized, multicenter, open-label Phase 3 study of gemcitabine-cisplatin chemotherapy plus necitumumab (IMC-11F8) versus gemcitabine-cisplatin chemotherapy alone in the first-line treatment of patients with stage IV squamous non-small cell lung cancer (NSCLC) (clinical trial registration No. NCT00981058)","year":"2022"},{"key":"B34","volume-title":"A randomized, multicenter, open-label Phase 3 study of pemetrexed-cisplatin chemotherapy plus necitumumab (IMC-11F8) versus pemetrexed-cisplatin chemotherapy alone in the first-line treatment of patients with stage IV nonsquamous non-small cell lung cancer (NSCLC) (clinical trial registration No. NCT00982111)","year":"2021"},{"key":"B35","volume-title":"A randomized, multicenter, open-label, Phase 2 study of paclitaxel-carboplatin chemotherapy plus necitumumab (IMC-11F8) versus paclitaxel-carboplatin chemotherapy alone in the first-line treatment of patients with stage IV squamous non-small cell lung cancer (NSCLC) (clinical trial registration No. NCT01769391)","year":""},{"key":"B36","volume-title":"EudraCT number 2011-000634-11 - clinical trial results - EU clinical trials register WWW document","year":"2011"},{"key":"B37","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1038\/nrcardio.2015.65","article-title":"Cardiotoxicity of anticancer treatments","volume":"12","author":"Ewer","year":"2015","journal-title":"Nat. Rev. Cardiol."},{"key":"B38","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1200\/JCO.1992.10.2.297","article-title":"Phase I-II study of high-dose epirubicin in advanced non-small-cell lung cancer","volume":"10","author":"Feld","year":"1992","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"B39","volume-title":"Global cancer observatory: Cancer today","author":"Ferlay","year":"2020"},{"key":"B40","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.lungcan.2019.01.008","article-title":"Randomized phase II study of pemetrexed or pemetrexed plus bevacizumab for elderly patients with previously untreated non-squamous non-small cell lung cancer: Results of the Lung Oncology Group in Kyushu (LOGIK1201)","volume":"132","author":"Fukuda","year":"2019","journal-title":"Lung Cancer"},{"key":"B41","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1093\/annonc\/mdh031","article-title":"Randomized phase II trial of gemcitabine\u2013cisplatin with or without trastuzumab in HER2-positive non-small-cell lung cancer","volume":"15","author":"Gatzemeier","year":"2004","journal-title":"Ann. Oncol."},{"key":"B42","volume-title":"A Phase II, open-label, multicenter, randomized study to assess the efficacy and safety of GSK1120212 compared with docetaxel in 2nd line subjects with targeted mutations (KRAS, NRAS, BRAF, MEK1) in locally advanced or metastatic non-small cell lung cancer (NSCLC stage IV) (clinical trial registration No. NCT01362296)","year":"2014"},{"key":"B43","volume-title":"Multi-arm, non-randomized, open-label Phase IB study to evaluate GSK3052230 in combination with paclitaxel and carboplatin, or docetaxel or as single agent in subjects with solid malignancies and deregulated FGF pathway signaling (clinical trial registration No. NCT01868022)","year":"2019"},{"key":"B44","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1002\/ijc.1295","article-title":"Use of paclitaxel in patients with pre-existing cardiomyopathy: A review of our experience","volume":"93","author":"Gollerkeri","year":"2001","journal-title":"Int. J. Cancer"},{"key":"B45","article-title":"Activity and toxicity of gemcitabine and gemcitabine +vinorelbine in advanced non-small-cell lung cancer elderly patients Phase II data from the Multicenter Italian Lung Cancer in the Elderly Study (MILES) randomized trial","volume":"8","author":"Gridelli","year":"2001","journal-title":"Lung Cancer"},{"key":"B46","doi-asserted-by":"publisher","first-page":"4320","DOI":"10.1200\/JCO.2011.35.5214","article-title":"Randomized, placebo-controlled phase III study of docetaxel plus carboplatin with celecoxib and cyclooxygenase-2 expression as a biomarker for patients with advanced non\u2013small-cell lung cancer: The NVALT-4 study","volume":"29","author":"Groen","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"B47","doi-asserted-by":"publisher","first-page":"e000665","DOI":"10.1161\/JAHA.113.000665","article-title":"Cancer therapy\u2013induced cardiotoxicity: Basic mechanisms and potential cardioprotective therapies","volume":"3","author":"Hahn","year":"2014","journal-title":"J. Am. Heart Assoc."},{"key":"B48","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1016\/j.lungcan.2013.02.007","article-title":"Prospective, multicenter, randomized, independent-group, open-label phase II study to investigate the efficacy and safety of three regimens with two doses of sagopilone as second-line therapy in patients with stage IIIB or IV non-small-cell lung cancer","volume":"80","author":"Heigener","year":"2013","journal-title":"Lung Cancer"},{"key":"B49","doi-asserted-by":"publisher","first-page":"1846","DOI":"10.1016\/S0140-6736(11)60545-X","article-title":"Efficacy of bevacizumab plus erlotinib versus erlotinib alone in advanced non-small-cell lung cancer after failure of standard first-line chemotherapy (BeTa): A double-blind, placebo-controlled, phase 3 trial","volume":"377","author":"Herbst","year":"2011","journal-title":"Lancet"},{"key":"B50","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/S0140-6736(17)30565-2","article-title":"Alectinib versus crizotinib in patients with ALK-positive non-small-cell lung cancer (J-ALEX): An open-label, randomised phase 3 trial","volume":"390","author":"Hida","year":"2017","journal-title":"Lancet lond. Engl."},{"key":"B51","volume-title":"Cochrane Handbook for systematic reviews of Interventions","author":"Higgins","year":"2022"},{"key":"B52","doi-asserted-by":"publisher","first-page":"1584","DOI":"10.1093\/jnci\/djq366","article-title":"Improved Estimates of cancer-specific survival rates from population-based data","volume":"102","author":"Howlader","year":"2010","journal-title":"JNCI J. Natl. Cancer Inst."},{"key":"B53","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1007\/s10637-019-00811-6","article-title":"A phase I dose-reduction study of apatinib combined with pemetrexed and carboplatin in untreated EGFR and ALK negative stage IV non-squamous NSCLC","volume":"38","author":"Huang","year":"2020","journal-title":"Invest. New Drugs"},{"key":"B54","volume-title":"Global oncology Trends 2021","year":"2021"},{"key":"B55","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1097\/JTO.0000000000000037","article-title":"Randomized, double-blind, phase II trial comparing gemcitabine-cisplatin plus the LTB4 antagonist LY293111 versus gemcitabine-cisplatin plus placebo in first-line non\u2013small-cell lung cancer","volume":"9","author":"J\u00e4nne","year":"2014","journal-title":"J. Thorac. Oncol."},{"key":"B56","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.1001\/jama.294.10.1255","article-title":"Trends in the leading causes of death in the United States, 1970-2002","volume":"294","author":"Jemal","year":"2005","journal-title":"JAMA"},{"key":"B57","doi-asserted-by":"publisher","first-page":"e9584","DOI":"10.1371\/journal.pone.0009584","article-title":"Declining death rates reflect progress against cancer","volume":"5","author":"Jemal","year":"2010","journal-title":"PLoS ONE"},{"key":"B58","first-page":"92","article-title":"Randomized controlled trial of endostar combined with cisplatin\/pemetrexed chemotherapy for elderly patients with advanced malignant pleural effusion of lung adenocarcinoma","volume":"23","author":"Jie Wang","year":"2018","journal-title":"J. BUON"},{"key":"B59","doi-asserted-by":"publisher","first-page":"3926","DOI":"10.1200\/JCO.2012.47.3983","article-title":"Atlas: Randomized, double-blind, placebo-controlled, phase IIIB trial comparing bevacizumab therapy with or without erlotinib, after completion of chemotherapy, with bevacizumab for first-line treatment of advanced non\u2013small-cell lung cancer","volume":"31","author":"Johnson","year":"2013","journal-title":"J. Clin. Oncol."},{"key":"B60","doi-asserted-by":"publisher","first-page":"2184","DOI":"10.1200\/JCO.2004.11.022","article-title":"Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer","volume":"22","author":"Johnson","year":"2004","journal-title":"J. Clin. Oncol."},{"key":"B61","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1007\/s40264-017-0596-0","article-title":"Erlotinib plus bevacizumab phase ll study in patients with advanced non-small-cell lung cancer (JO25567): Updated safety results","volume":"41","author":"Kato","year":"2018","journal-title":"Drug Saf."},{"key":"B62","doi-asserted-by":"publisher","first-page":"908","DOI":"10.1038\/nm1446","article-title":"Cardiotoxicity of the cancer therapeutic agent imatinib mesylate","volume":"12","author":"Kerkel\u00e4","year":"2006","journal-title":"Nat. Med."},{"key":"B63","doi-asserted-by":"publisher","first-page":"1546","DOI":"10.1016\/j.ejca.2011.03.035","article-title":"Effect of celecoxib on survival in patients with advanced non-small cell lung cancer: A double blind randomised clinical phase III trial (cyclus study) by the Swedish lung cancer study group","volume":"47","author":"Koch","year":"2011","journal-title":"Eur. J. Cancer"},{"key":"B64","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1093\/annonc\/mdm430","article-title":"Paclitaxel and gemcitabine versus carboplatin and gemcitabine in patients with advanced non-small-cell lung cancer. A phase III study of the Hellenic Cooperative Oncology Group","volume":"19","author":"Kosmidis","year":"2008","journal-title":"Ann. Oncol."},{"key":"B65","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.lungcan.2015.01.012","article-title":"Sequential administration of vinorelbine plus cisplatin and bevacizumab followed by docetaxel plus gemcitabine and bevacizumab compared to docetaxel plus cisplatin and bevacizumab regimen as first-line therapy for advanced or metastatic non-squamous non-small cell lung cancer: A multicenter randomized phase II trial of the hellenic oncology research group (horg)","volume":"88","author":"Kotsakis","year":"2015","journal-title":"Lung Cancer"},{"key":"B66","doi-asserted-by":"publisher","first-page":"3662","DOI":"10.1200\/JCO.2017.72.7297","article-title":"Phase III, randomized, placebo-controlled, double-blind trial of motesanib (AMG-706) in combination with paclitaxel and carboplatin in east asian patients with advanced nonsquamous non\u2013small-cell lung cancer","volume":"35","author":"Kubota","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"B67","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1016\/j.cllc.2017.04.003","article-title":"Safety analyses of pemetrexed-cisplatin and pemetrexed maintenance therapies in patients with advanced non-squamous NSCLC: Retrospective analyses from 2 phase III studies","volume":"18","author":"Langer","year":"2017","journal-title":"Clin. Lung Cancer"},{"key":"B68","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1016\/j.jtho.2015.11.003","article-title":"Swog S0709: Randomized phase II trial of erlotinib versus erlotinib plus carboplatin\/paclitaxel in patients with advanced non\u2013small cell lung cancer and impaired performance status as selected by a serum proteomics assay","volume":"11","author":"Lara","year":"2016","journal-title":"J. Thorac. Oncol."},{"key":"B69","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1016\/j.redox.2015.09.007","article-title":"Treatment of sunitinib-induced hypertension in solid tumor by nitric oxide donors","volume":"6","author":"Le\u00f3n-Mateos","year":"2015","journal-title":"Redox Biol."},{"key":"B70","doi-asserted-by":"publisher","first-page":"3219","DOI":"10.1200\/JCO.2013.48.8585","article-title":"Apatinib for chemotherapy-refractory advanced metastatic gastric cancer: Results from a randomized, placebo-controlled, parallel-arm, phase II trial","volume":"31","author":"Li","year":"2013","journal-title":"J. Clin. Oncol."},{"key":"B71","doi-asserted-by":"publisher","first-page":"S19","DOI":"10.1093\/annonc\/10.suppl_5.S19","article-title":"Anthracyclines in non-small-cell lung cancer: Do they have a therapeutic role?","volume":"10","author":"Martoni","year":"1999","journal-title":"Ann. Oncol."},{"key":"B72","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.1016\/0277-5379(91)90087-T","article-title":"Activity of high-dose epirubicin in advanced non-small cell lung cancer","volume":"27","author":"Martoni","year":"1991","journal-title":"Eur. J. Cancer"},{"key":"B73","doi-asserted-by":"publisher","first-page":"S19","DOI":"10.2459\/JCM.0000000000000377","article-title":"Pathophysiology of cardiotoxicity from target therapy and angiogenesis inhibitors","volume":"17","author":"Maurea","year":"2016","journal-title":"J. Cardiovasc. Med."},{"key":"B74","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1007\/s10557-016-6711-0","article-title":"Anthracycline chemotherapy and cardiotoxicity","volume":"31","author":"McGowan","year":"2017","journal-title":"Cardiovasc. Drugs Ther."},{"key":"B75","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1093\/toxsci\/kfq378","article-title":"Cardiotoxicity associated with targeting kinase pathways in cancer","volume":"120","author":"Mellor","year":"2011","journal-title":"Toxicol. Sci. Off. J. Soc. Toxicol."},{"key":"B76","doi-asserted-by":"publisher","first-page":"2490","DOI":"10.3390\/toxins2112490","article-title":"Mechanisms of cisplatin nephrotoxicity","volume":"2","author":"Miller","year":"2010","journal-title":"Toxins"},{"key":"B77","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.1007\/s00280-015-2876-7","article-title":"A phase 1 study evaluating the pharmacokinetics and preliminary efficacy of veliparib (ABT-888) in combination with carboplatin\/paclitaxel in Japanese subjects with non-small cell lung cancer (NSCLC)","volume":"76","author":"Mizugaki","year":"2015","journal-title":"Cancer Chemother. Pharmacol."},{"key":"B78","doi-asserted-by":"publisher","first-page":"1457","DOI":"10.1056\/NEJMra1100265","article-title":"Cardiovascular toxic effects of targeted cancer therapies","volume":"375","author":"Moslehi","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"B79","doi-asserted-by":"publisher","first-page":"2145","DOI":"10.1200\/JCO.2005.07.167","article-title":"Randomized trial of amifostine in locally advanced non\u2013small-cell lung cancer patients receiving chemotherapy and hyperfractionated radiation: Radiation therapy oncology group trial 98-01","volume":"23","author":"Movsas","year":"2005","journal-title":"J. Clin. Oncol."},{"key":"B80","first-page":"1132","article-title":"Cardiotoxicity of chemotherapy and targeted agents","volume":"11","author":"Mudd","year":"2021","journal-title":"Am. J. Cancer Res."},{"key":"B81","volume-title":"A Phase II randomized study of OSI-774 (erlotinib) (NSC #718781) with or without carboplatin\/paclitaxel in patients with previously untreated adenocarcinoma of the lung who never smoked or were former light smokers (clinical trial registration No. NCT00126581)","year":"2019"},{"key":"B82","doi-asserted-by":"publisher","first-page":"1154","DOI":"10.1097\/JTO.0000000000000227","article-title":"Motesanib plus carboplatin\/paclitaxel in patients with advanced squamous non-small-cell lung cancer results from the randomized controlled MONET1 study","volume":"9","author":"Novello","year":"","journal-title":"J. Thorac. Oncol."},{"key":"B83","doi-asserted-by":"publisher","first-page":"2156","DOI":"10.1093\/annonc\/mdu384","article-title":"A phase II randomized study evaluating the addition of iniparib to gemcitabine plus cisplatin as first-line therapy for metastatic non-small-cell lung cancer","volume":"25","author":"Novello","year":"","journal-title":"Ann. Oncol. Off. J. Eur. Soc. Med. Oncol."},{"key":"B85","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/j.ejphar.2017.05.063","article-title":"Cisplatin induced arrhythmia; electrolyte imbalance or disturbance of the SA node?","volume":"811","author":"Oun","year":"2017","journal-title":"Eur. J. Pharmacol."},{"key":"B86","doi-asserted-by":"publisher","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: An updated guideline for reporting systematic reviews","author":"Page","year":"","journal-title":"BMJ"},{"key":"B87","doi-asserted-by":"publisher","first-page":"n160","DOI":"10.1136\/bmj.n160","article-title":"PRISMA 2020 explanation and elaboration: Updated guidance and exemplars for reporting systematic reviews","author":"Page","year":"","journal-title":"BMJ"},{"key":"B88","doi-asserted-by":"publisher","first-page":"e289","DOI":"10.1016\/j.cllc.2017.01.002","article-title":"Randomized phase III study of docetaxel plus cisplatin versus pemetrexed plus cisplatin as first-line treatment of nonsquamous non-small-cell lung cancer: A trail trial","volume":"18","author":"Park","year":"2017","journal-title":"Clin. Lung Cancer"},{"key":"B89","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1186\/1479-5876-6-65","article-title":"Randomized phase II study with two gemcitabine- and docetaxel-based combinations as first-line chemotherapy for metastatic non-small cell lung cancer","volume":"6","author":"Passardi","year":"2008","journal-title":"J. Transl. Med."},{"key":"B90","doi-asserted-by":"publisher","first-page":"1745","DOI":"10.1097\/JTO.0000000000000693","article-title":"Monotherapy administration of sorafenib in patients with non-small cell lung cancer (MISSION) trial: A phase III, multicenter, placebo-controlled trial of sorafenib in patients with relapsed or refractory predominantly nonsquamous non-small-cell lung cancer after 2 or 3 previous treatment regimens","volume":"10","author":"Paz-Ares","year":"2015","journal-title":"J. Thorac. Oncol."},{"key":"B91","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1200\/JCO.2004.01.120","article-title":"Clinical cardiac tolerability of trastuzumab","volume":"22","author":"Perez","year":"2004","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"B92","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1016\/j.lungcan.2015.08.003","article-title":"Anti-angiogenic-specific adverse events in patients with non-small cell lung cancer treated with nintedanib and docetaxel","volume":"90","author":"Reck","year":"2015","journal-title":"Lung Cancer"},{"key":"B93","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1007\/s40259-019-00363-4","article-title":"PF-06439535 (a bevacizumab biosimilar) compared with reference bevacizumab (Avastin\u00ae), both plus paclitaxel and carboplatin, as first-line treatment for advanced non-squamous non-small-cell lung cancer: A randomized, double-blind study","volume":"33","author":"Reinmuth","year":"2019","journal-title":"BioDrugs"},{"key":"B94","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1007\/BF03006439","article-title":"Assessment of fatty acid metabolism in taxan-induced myocardial damage with iodine-123 BMIPP SPECT: Comparative study with myocardial perfusion, left ventricular function, and histopathological findings","volume":"17","author":"Saito","year":"2003","journal-title":"Ann. Nucl. Med."},{"key":"B95","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/j.ctrv.2017.07.006","article-title":"Incidence and risk of cardiotoxicity in cancer patients treated with targeted therapies","volume":"59","author":"Santoni","year":"2017","journal-title":"Cancer Treat. Rev."},{"key":"B96","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1007\/s00262-019-02315-x","article-title":"A phase I\/IIa study of the mRNA-based cancer immunotherapy CV9201 in patients with stage IIIB\/IV non-small cell lung cancer","volume":"68","author":"Sebastian","year":"2019","journal-title":"Cancer Immunol. Immunother. CII"},{"key":"B97","doi-asserted-by":"publisher","first-page":"3327","DOI":"10.1200\/JCO.2012.44.2806","article-title":"Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations","volume":"31","author":"Sequist","year":"2013","journal-title":"J. Clin. Oncol."},{"key":"B98","doi-asserted-by":"publisher","first-page":"1236","DOI":"10.1016\/S1470-2045(14)70381-X","article-title":"Erlotinib alone or with bevacizumab as first-line therapy in patients with advanced non-squamous non-small-cell lung cancer harbouring EGFR mutations (JO25567): An open-label, randomised, multicentre, phase 2 study","volume":"15","author":"Seto","year":"2014","journal-title":"Lancet Oncol."},{"key":"B99","doi-asserted-by":"publisher","first-page":"2557","DOI":"10.1080\/10428194.2018.1437269","article-title":"Cardiotoxicity associated with carfilzomib: Systematic review and meta-analysis","volume":"59","author":"Shah","year":"2018","journal-title":"Leuk. Lymphoma"},{"key":"B100","doi-asserted-by":"publisher","first-page":"2385","DOI":"10.1056\/NEJMoa1214886","article-title":"Crizotinib versus chemotherapy in advanced ALK -positive lung cancer","volume":"368","author":"Shaw","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"B101","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1038\/bjc.1992.82","article-title":"A phase II study of high dose epirubicin in unresectable non small cell lung cancer","volume":"65","author":"Smit","year":"1992","journal-title":"Br. J. Cancer"},{"key":"B102","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1186\/1471-2407-10-337","article-title":"Cardiotoxicity of anthracycline agents for the treatment of cancer: Systematic review and meta-analysis of randomised controlled trials","volume":"10","author":"Smith","year":"2010","journal-title":"BMC Cancer"},{"key":"B103","doi-asserted-by":"publisher","first-page":"2167","DOI":"10.1056\/NEJMoa1408440","article-title":"First-line crizotinib versus chemotherapy in ALK -positive lung cancer","volume":"371","author":"Solomon","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"B104","doi-asserted-by":"publisher","first-page":"27","DOI":"10.4103\/ccij.ccij_94_19","article-title":"A randomized prospective study comparing concomitant chemoradiotherapy using paclitaxel-carboplatin with concomitant chemoradiotherapy using etoposide-cisplatin in inoperable or nonresectable locally advanced non-small cell lung cancer","volume":"9","author":"Srinivasa","year":"2020","journal-title":"Clin. Cancer Investig. J."},{"key":"B105","doi-asserted-by":"publisher","first-page":"1048","DOI":"10.1093\/annonc\/mdh260","article-title":"Front-line paclitaxel\u2013vinorelbine versus paclitaxel\u2013carboplatin in patients with advanced non-small-cell lung cancer: A randomized phase III trial","volume":"15","author":"Stathopoulos","year":"2004","journal-title":"Ann. Oncol."},{"key":"B106","doi-asserted-by":"publisher","first-page":"2869","DOI":"10.1002\/cncr.11407","article-title":"Congestive heart failure in patients treated with doxorubicin: A retrospective analysis of three trials","volume":"97","author":"Swain","year":"2003","journal-title":"Cancer"},{"key":"B107","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1002\/1097-0142(1967)20:3<333:AID-CNCR2820200302>3.0.CO;2-K","article-title":"Daunomycin, an antitumor antibiotic, in the treatment of neoplastic disease.Clinical evaluation with special reference to childhood leukemia","volume":"20","author":"Tan","year":"1967","journal-title":"Cancer"},{"key":"B108","doi-asserted-by":"publisher","first-page":"2110","DOI":"10.1089\/ars.2016.6930","article-title":"From molecular mechanisms to clinical management of antineoplastic drug-induced cardiovascular toxicity: A translational overview","volume":"30","author":"Tocchetti","year":"2019","journal-title":"Antioxid. Redox Signal."},{"key":"B109","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1002\/1097-0142(19891115)64:10<1995:aid-cncr2820641004>3.0.co;2-l","article-title":"Weekly doxorubicin versus doxorubicin every 3 weeks in cyclophosphamide, doxorubicin, and cisplatin chemotherapy for non-small cell lung cancer","volume":"64","author":"Umsawasdi","year":"1989","journal-title":"Cancer"},{"key":"B110","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1200\/JCO.1984.2.3.207","article-title":"Increased therapeutic index of weekly doxorubicin in the therapy of non-small cell lung cancer: A prospective, randomized study","volume":"2","author":"Valdivieso","year":"1984","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"B111","article-title":"Cardiotoxicity in advanced non-small-cell lung cancer (NSCLC) patients treated with gemcitabine and either epirubicin or cisplatin as first-line treatment","volume":"659","author":"Wachters","year":"2003","journal-title":"Proc. Am. Soc. Clin. Oncol."},{"key":"B112","first-page":"2079","article-title":"Cardiotoxicity in advanced non-small cell lung cancer patients treated with platinum and non-platinum based combinations as first-line treatment","volume":"24","author":"Wachters","year":"2004","journal-title":"Anticancer Res."},{"key":"B113","doi-asserted-by":"publisher","first-page":"2046","DOI":"10.1002\/1097-0142(197711)40:5<2046:aid-cncr2820400508>3.0.co;2-5-5","article-title":"Experience with the use of adriamycin in combination with other anticancer agents using a weekly schedule, with particular reference to lack of cardiac toxicity","volume":"40","author":"Weiss","year":"1977","journal-title":"Cancer"},{"key":"B114","first-page":"813","article-title":"Studies on adriamycin using a weekly regimen demonstrating its clinical effectiveness and lack of cardiac toxicity","volume":"60","author":"Weiss","year":"1976","journal-title":"Cancer Treat. Rep."},{"key":"B115","volume-title":"WHOCC","year":"2022"},{"key":"B116","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1097\/JTO.0b013e31811f4719","article-title":"Phase I trial of motexafin gadolinium in combination with docetaxel and cisplatin for the treatment of non-small cell lung cancer","volume":"2","author":"William","year":"2007","journal-title":"J. Thorac. Oncol."},{"key":"B117","doi-asserted-by":"publisher","first-page":"1140","DOI":"10.1016\/0277-5379(90)90271-T","article-title":"Phase II study of high-dose epirubicin in non-small cell lung cancer","volume":"26","author":"Wils","year":"1990","journal-title":"Eur. J. Cancer Clin. Oncol."},{"key":"B118","volume-title":"Global Health Estimates","year":"2020"},{"key":"B119","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/S1470-2045(08)70003-2","article-title":"Incidence and risk of hypertension with sorafenib in patients with cancer: A systematic review and meta-analysis","volume":"9","author":"Wu","year":"2008","journal-title":"Lancet Oncol."},{"key":"B120","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.1016\/S2213-2600(20)30154-5","article-title":"Tepotinib plus gefitinib in patients with EGFR-mutant non-small-cell lung cancer with MET overexpression or MET amplification and acquired resistance to previous EGFR inhibitor (INSIGHT study): An open-label, phase 1b\/2, multicentre, randomised trial","volume":"8","author":"Wu","year":"2020","journal-title":"Lancet Respir. Med."},{"key":"B121","doi-asserted-by":"publisher","first-page":"e465","DOI":"10.1016\/j.cllc.2018.03.009","article-title":"Afatinib as first-line treatment of older patients with EGFR mutation-positive non-small-cell lung cancer: Subgroup analyses of the LUX-lung 3, LUX-lung 6, and LUX-lung 7 trials","volume":"19","author":"Wu","year":"2018","journal-title":"Clin. Lung Cancer"},{"key":"B122","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1093\/annonc\/mdw621","article-title":"A randomized, open-label, phase III trial comparing amrubicin versus docetaxel in patients with previously treated non-small-cell lung cancer","volume":"28","author":"Yoshioka","year":"2017","journal-title":"Ann. Oncol. Off. J. Eur. Soc. Med. Oncol."},{"key":"B123","doi-asserted-by":"publisher","first-page":"1268","DOI":"10.3390\/jcm9051268","article-title":"Cardiovascular complications of systemic therapy in non-small-cell lung cancer","volume":"9","author":"Zaborowska-Szmit","year":"2020","journal-title":"J. Clin. Med."},{"key":"B124","doi-asserted-by":"publisher","first-page":"125","DOI":"10.2147\/OTT.S42245","article-title":"Docetaxel-carboplatin in combination with erlotinib and\/or bevacizumab in patients with non-small cell lung cancer","volume":"125","author":"Zarogoulidis","year":"2013","journal-title":"OncoTargets Ther."},{"key":"B125","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/j.lungcan.2004.03.004","article-title":"Concurrent versus sequential chemoradiotherapy with cisplatin and vinorelbine in locally advanced non-small cell lung cancer: A randomized study","volume":"46","author":"Zatloukal","year":"2004","journal-title":"Lung Cancer"},{"key":"B126","doi-asserted-by":"publisher","first-page":"1639","DOI":"10.1038\/nm.2919","article-title":"Identification of the molecular basis of doxorubicin-induced cardiotoxicity","volume":"18","author":"Zhang","year":"2012","journal-title":"Nat. Med."},{"key":"B127","doi-asserted-by":"publisher","first-page":"116526","DOI":"10.1016\/j.lfs.2019.06.001","article-title":"Role of oxidative stress in cardiotoxicity of antineoplastic drugs","volume":"232","author":"Zhang","year":"2019","journal-title":"Life Sci."},{"key":"B128","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1097\/JTO.0000000000000366","article-title":"Pronounce: Randomized, open-label, phase III study of first-line pemetrexed + carboplatin followed by maintenance pemetrexed versus paclitaxel + carboplatin + bevacizumab followed by maintenance bevacizumab in patients ith advanced nonsquamous non\u2013small-cell lung cancer","volume":"10","author":"Zinner","year":"2015","journal-title":"J. Thorac. Oncol."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2023.1137983\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,13]],"date-time":"2023-06-13T04:41:50Z","timestamp":1686631310000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2023.1137983\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,13]]},"references-count":127,"alternative-id":["10.3389\/fphar.2023.1137983"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2023.1137983","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6,13]]},"article-number":"1137983"}}